跳至主要内容
临床试验/JPRN-UMIN000031070
JPRN-UMIN000031070已完成未知

Efficacy and safety of liraglutide for perioperative blood glucose control in diabetic subjects within enhanced recovery after surgery (ERAS) protocols - Randomized prospective study for perioperative diabetes control within enhanced recovery after surgery (ERAS) protocols

Takatsuki redcross hospital0 个研究点目标入组 100 人开始时间: 2018年1月31日最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
100

研究概览

简要总结

iraglutide was shown to be a more effective option than insulin therapy because (1) glycemic levels were more stable; (2) the number of patients requiring additional insulin according to the insulin sliding scale was significantly smaller (p = 0.005); (3) the insulin dosage required on the day of surgery was significantly smaller (p = 0.004); (4) the additional insulin volume required was significantly less for patients throughout the perioperative period (p = 0.001).

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • Patients who were to undergo gastrointestinal or neurosurgical procedures were excluded. Patients who tested positive for anti-GAD (glutamate decarboxylase) antibodies or with elevated ALT (2 times upper normal range) were excluded from the study. Patients with autonomic neuropathy or recurrent severe hypoglycemia were also excluded. Patients who had been administered any drug except for oral antidiabetic drugs (OADs), which could interfere with glucose level or bodyweight (i.e. systemic corticosteroids, orlistat or sibutramine), were also excluded. Patients who had been administered sGLT-2 inhibitor or thiazolidinediones were excluded because these medicines could interfere with accurate bodyweight changes

研究者

发起方
Takatsuki redcross hospital

相似试验